Waldeck B
Astra Draco AB, Lund, Sweden.
Chirality. 1993;5(5):350-5. doi: 10.1002/chir.530050514.
The knowledge that enantiomers of chiral compounds may differ widely in biological activity, qualitatively as well as quantitatively, is not new. Nevertheless most of the pharmacological data available to date on chiral drugs are obtained from experiments with racemates which assume that the biological activity generally resides in one of the enantiomers. With the advancements made in stereospecific synthesis and stereoselective analysis of drugs pharmacologists are now offered new possibilities to explore the steric aspects of drug action. This survey will discuss pharmacological data obtained with enantiomer pairs of phenylethylamine derivatives which interact with adrenergic mechanisms. The degree of resolution is seldom specified in published work on stereoselectivity of drugs. In a recent study from our laboratory the enantiomers of the beta 2-adrenoceptor agonist formoterol and their diastereomers have been evaluated. We found that the (R;R)-enantiomer was by far the most potent. However, the relative potencies obtained for the (R;S)-, (S;R), and (S;S)-isomers were critically dependent on the degree of enantiomeric purity. It is concluded that the certainty of potency ratios observed for chiral drugs is limited by the enantiomeric purity and by unspecific effects of the least active enantiomer at very high concentrations.
手性化合物的对映体在生物活性上可能在质和量方面都存在很大差异,这一认识并不新鲜。然而,迄今为止大多数关于手性药物的药理学数据是通过外消旋体实验获得的,这些实验假定生物活性通常存在于其中一种对映体中。随着药物立体特异性合成和立体选择性分析技术的进步,药理学家现在有了探索药物作用空间方面的新可能性。本综述将讨论与肾上腺素能机制相互作用的苯乙胺衍生物对映体对所获得的药理学数据。在已发表的关于药物立体选择性的研究中,很少明确指出拆分程度。在我们实验室最近的一项研究中,对β2 -肾上腺素能受体激动剂福莫特罗的对映体及其非对映体进行了评估。我们发现(R;R)-对映体的活性最强。然而,(R;S)-、(S;R)-和(S;S)-异构体的相对效价严重依赖于对映体纯度。得出的结论是,手性药物效价比的确定性受到对映体纯度以及高浓度下活性最低的对映体的非特异性效应的限制。